v3.26.1
INVENTORIES
 3 Months Ended
Mar. 31, 2026
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
The following table shows the Company’s inventory by asset class as of the dates indicated:
(in thousands)March 31, 2026December 31, 2025
Raw materials$83,333 $84,106 
Work-in-progress5,290 2,973 
Finished goods54,845 55,988 
Inventories$143,468 $143,067 
Vendor Concentration
Raw materials are sourced for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon its current vendors to reliably supply the API required for on-going product manufacturing. During the three months ended March 31, 2026, approximately 33%, of the Company’s raw material inventory purchases were from one domestic supplier. During the three months ended March 31, 2025, approximately 22% of the Company’s raw material inventory purchases were from one domestic supplier.